Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9662518 | 0.92 | KCNH2 (0.45) | KCNH2CA12CA1CA9CA2 | |
| SCHEMBL9672034 | 0.85 | CA12 (0.47) | KCNH2CA12CA1CA9CA2 | |
| SCHEMBL6338672 | 0.84 | KCNH2 (0.46) | KCNH2CA12CA1CA9CA2 | |
| SCHEMBL15807615 | 0.81 | PTPN2 (0.47) | CA12CA1CA9CA2BCHE | |
| SCHEMBL11484074 | 0.81 | ALDH1A1 (0.41) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL12143087 | 0.79 | CA12 (0.42) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL6880345 | 0.79 | MMP3 (0.45) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL3909229 | 0.77 | CYP2A6 (0.41) | KCNH2CA12CA1CA9CA2 | |
| SCHEMBL6299975 | 0.77 | KCNH2 (0.46) | KCNH2CA12CA1CA9CA2 | |
| SCHEMBL7723972 | 0.77 | CNR2 (0.54) | KCNH2BCHEACHEALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949661-B2 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-6861445-B2 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-6784184-B2 | FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES | WYETH HOLDINGS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-6740675-B2 | ANTICANCER THERAPY | WYETH HOLDINGS CORPORATION | 2004-05-25 | — | — | US | disclosed |
| US-20040063971-A1 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-20040063777-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | WYETH HOLDINGS CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6605628-B1 | Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis | WYETH HOLDINGS CORPORATION | 2003-08-12 | — | — | US | disclosed |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-08-07 | — | — | US | disclosed |
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030083364-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase | AMERICAN CYANAMID COMPANY | 2003-05-01 | — | — | US | disclosed |
| WO-2003018135-A1 | METHOD OF USING 5-(ARYLSULFONYL)-,5-(ARYLSULFINYL), AND 5-(ARYLSULFANYL)-THIAZOLIDINE-2,4-DIONES FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE | WYETH HOLDINGS CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144301-A1 | Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase | FNTB, FNTA, TST | KCNH2 4716/4885CA12 4473/4885CA1 4014/4885 |
| US-20040063777-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | KCNH2 4743/4885CA12 3776/4885CA1 2464/4885 |
| US-20030149063-A1 | 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase | FNTB, FNTA, NAT1 | KCNH2 4762/4885CA12 4692/4885CA1 4153/4885 |
| US-20030083364-A1 | 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | KCNH2 4763/4885CA12 3626/4885CA1 2527/4885 |
| US-20040063971-A1 | 3-substituted-3-(substitutedsulfonyl or sulfanyl) pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase | FNTA, FNTB, FDPS | KCNH2 4743/4885CA12 3776/4885CA1 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.